Company BioXcel Therapeutics, Inc.

BTAI

US09075P2048

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2025-12-05 EST			5-day change	1st Jan Change
2.070 ^USD	-0.96%		-8.00%	-65.40%

11-12	BioXcel Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-12	BioXcel Therapeutics Q3 revenue misses analyst expectations	RE

Business description: BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Companyâs most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Number of employees: 37

Sales by Activity: BioXcel Therapeutics, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
Pharmaceuticals	-	-	375K	1.38M	2.27M

See all business segments

Geographical breakdown of sales: BioXcel Therapeutics, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
United States	-	-	375K	1.38M	2.27M

See all geographic segments

Executive Committee: BioXcel Therapeutics, Inc.

Manager	Title	Age	Since
Vimal Mehta CEO	Chief Executive Officer	64	2017-04-30
Richard Steinhart DFI	Director of Finance/CFO	67	2017-09-30
Frank Yocca CTO	Chief Tech/Sci/R&D Officer	69	2017-05-31
Javier Rodriguez LAW	General Counsel	53	2021-02-22

See BIOXCEL THERAPEUTICS, INC. governance

Composition of the Board of Directors: BioXcel Therapeutics, Inc.

Director	Title	Age	Since
Peter Mueller CHM	Chairman	69	2017-07-31
Sandeep Laumas BRD	Director/Board Member	57	2017-08-31
Vimal Mehta BRD	Director/Board Member	64	2017-03-31
Michal Votruba BRD	Director/Board Member	60	2019-03-06
June Bray BRD	Director/Board Member	72	2021-02-28
Michael Miller BRD	Director/Board Member	68	2021-12-31
David Mack BRD	Director/Board Member	55	2024-11-20
Rajiv Patni BRD	Director/Board Member	67	2025-01-14

Composition of the Board of Directors

Shareholders: BioXcel Therapeutics, Inc.

Name	Equities	%	Valuation
Millennium Management LLC 7.062 %	1,028,053	7.062 %	2 M $
BioXcel Corp. 3.3 %	480,343	3.3 %	984 703 $
Oaktree Capital Management LP 1.657 %	241,188	1.657 %	494 435 $
Fidelity Management & Research Co. LLC 1.364 %	198,600	1.364 %	407 130 $
Vanguard Fiduciary Trust Co. 1.32 %	192,125	1.32 %	393 856 $

List of BIOXCEL THERAPEUTICS, INC. shareholders

Company details: BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc.

555 Long Wharf Drive

06511, New Haven

+475 238 6837

http://www.bioxceltherapeutics.com

address BioXcel Therapeutics, Inc.(BTAI)

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BIOXCEL THERAPEUTICS, INC.	-0.96%	-8.00%	-68.27%	-99.30%	45.27M
ELI LILLY AND COMPANY	-0.41%	-6.06%	+22.21%	+174.14%	905B
JOHNSON & JOHNSON	-0.27%	-2.41%	+35.24%	+14.67%	487B
ABBVIE INC.	-1.15%	-0.71%	+28.32%	+38.09%	400B
ROCHE HOLDING AG	+0.26%	+1.14%	+20.97%	+1.87%	330B
ASTRAZENECA PLC	+0.58%	-2.73%	+27.58%	+21.90%	281B
NOVARTIS AG	+0.19%	+2.49%	+19.23%	+25.56%	255B
MERCK & CO., INC.	-1.16%	-4.87%	-3.27%	-8.45%	248B
NOVO NORDISK A/S	+1.24%	-2.33%	-60.59%	-30.82%	214B
AMGEN INC.	-3.02%	-4.51%	+21.03%	+16.45%	178B
Average	-0.47%	-2.80%	+4.24%	+15.41%	329.66B
Weighted average by Cap.	-0.37%	-2.79%	+17.62%	+56.85%